Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 7
2002 71
2003 85
2004 101
2005 94
2006 114
2007 113
2008 139
2009 125
2010 159
2011 167
2012 152
2013 136
2014 122
2015 131
2016 130
2017 90
2018 89
2019 71
2020 99
2021 105
2022 84
2023 62
2024 58
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,275 results

Results by year

Filters applied: . Clear all
Page 1
Fondaparinux Sodium: Recent Advances in the Management of Thrombosis.
Bauersachs RM. Bauersachs RM. J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484221145010. doi: 10.1177/10742484221145010. J Cardiovasc Pharmacol Ther. 2023. PMID: 36594404 Free article. Review.
Since its approval in 2002, the efficacy and safety of fondaparinux is well demonstrated by many clinical studies, establishing the value of fondaparinux in clinical practice. ...The emerging data from these studies have culminated in recent updates in the guideline …
Since its approval in 2002, the efficacy and safety of fondaparinux is well demonstrated by many clinical studies, establishing the v …
When Will Fondaparinux Induce Thrombocytopenia?
Chen LY, Khan N, Lindenbauer A, Nguyen TH. Chen LY, et al. Bioconjug Chem. 2022 Aug 17;33(8):1574-1583. doi: 10.1021/acs.bioconjchem.2c00316. Epub 2022 Jul 25. Bioconjug Chem. 2022. PMID: 35878320 Free PMC article.
However, some observations of Fondaparinux-induced thrombocytopenia (FIT) have been reported while others claimed that FIT does not occur in patients with fondaparinux therapy, indicating that the mechanism of FIT remains controversial. ...Our results clarify contro …
However, some observations of Fondaparinux-induced thrombocytopenia (FIT) have been reported while others claimed that FIT does not o …
Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis.
Kumar A, Talwar A, Farley JF, Muzumdar J, Schommer JC, Balkrishnan R, Wu W. Kumar A, et al. J Am Heart Assoc. 2019 May 21;8(10):e012184. doi: 10.1161/JAHA.119.012184. J Am Heart Assoc. 2019. PMID: 31070069 Free PMC article.
Pooled analyses showed the odds of venous thromboembolism in the fondaparinux group were 0.49 times the odds in LMWH group ( OR =0.49 [0.38-0.64]). However, the odds of major bleeding in the fondaparinux group were 1.48 times the odds in the LMWH group ( OR =1.48 [1 …
Pooled analyses showed the odds of venous thromboembolism in the fondaparinux group were 0.49 times the odds in LMWH group ( OR =0.49 …
The clinical use of Fondaparinux: A synthetic heparin pentasaccharide.
Zhang Y, Zhang M, Tan L, Pan N, Zhang L. Zhang Y, et al. Prog Mol Biol Transl Sci. 2019;163:41-53. doi: 10.1016/bs.pmbts.2019.02.004. Epub 2019 Mar 21. Prog Mol Biol Transl Sci. 2019. PMID: 31030756 Review.
Fondaparinux is a synthetic heparin pentasaccharide with a sequence identical to that found in anticoagulant heparin. ...Low antithrombin III levels in blood circulation also affects the efficacy of Fondaparinux. Thus, Fondaparinux represents a refined use of …
Fondaparinux is a synthetic heparin pentasaccharide with a sequence identical to that found in anticoagulant heparin. ...Low antithro …
Low-Molecular-Weight Heparin and Fondaparinux Use in Pediatric Patients With Obesity.
Garner MP, Onuoha CP, Fenn NE 3rd. Garner MP, et al. Ann Pharmacother. 2021 May;55(5):666-676. doi: 10.1177/1060028020955029. Epub 2020 Aug 30. Ann Pharmacother. 2021. PMID: 32864984 Review.
Search terms utilized included LMWH, low-molecular-weight heparin, enoxaparin, dalteparin, tinzaparin, fondaparinux, pediatric, child, children, obese, obesity, overweight. No limits or timeline restrictions were imposed. ...Trends could not be concluded in the dalteparin …
Search terms utilized included LMWH, low-molecular-weight heparin, enoxaparin, dalteparin, tinzaparin, fondaparinux, pediatric, child …
Fondaparinux in acute coronary syndromes.
Chaturvedi V, Karthikeyan G. Chaturvedi V, et al. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1615-23. doi: 10.1517/17425250903456039. Expert Opin Drug Metab Toxicol. 2009. PMID: 19929450 Review.
These studies have shown a significantly lower risk of bleeding with fondaparinux compared to heparins, with equivalent or greater reductions in ischemic outcomes. ...This review outlines the pharmacological properties of fondaparinux and critically examines the ava …
These studies have shown a significantly lower risk of bleeding with fondaparinux compared to heparins, with equivalent or greater re …
Fondaparinux: a new antithrombotic agent.
Cheng JW. Cheng JW. Clin Ther. 2002 Nov;24(11):1757-69; discussion 1719. doi: 10.1016/s0149-2918(02)80077-7. Clin Ther. 2002. PMID: 12501872 Review.
CONCLUSIONS: Fondaparinux has shown efficacy in the prevention of venous thromboembolism in patients undergoing hip or knee replacement surgery. ...Routine use of fondaparinux as a replacement for low-molecular-weight heparin is not recommended at this time....
CONCLUSIONS: Fondaparinux has shown efficacy in the prevention of venous thromboembolism in patients undergoing hip or knee replaceme …
Fondaparinux for Management of Heparin-induced Thrombocytopenia after Cardiovascular Intervention: A Systematic Review.
Bhatt VR, Dahal S, Verma V, Shukla P, Khanal N, Pathak R, Giri S. Bhatt VR, et al. Cardiovasc Hematol Agents Med Chem. 2015;13(2):82-6. doi: 10.2174/1871525713666150911113811. Cardiovasc Hematol Agents Med Chem. 2015. PMID: 26362274 Review.
OBJECTIVES: The efficacy and safety of fondaparinux, an emerging therapeutic option for heparin-induced thrombocytopenia (HIT), remain unclear in cardiac surgery patients with HIT. ...Overall the risk of new thrombosis and bleeding with fondaparinux were 4.6% and 7% …
OBJECTIVES: The efficacy and safety of fondaparinux, an emerging therapeutic option for heparin-induced thrombocytopenia (HIT), remai …
Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: A meta-analysis.
Mu F, Wang M, Huang J, Wang F. Mu F, et al. Eur J Obstet Gynecol Reprod Biol. 2023 Aug;287:29-35. doi: 10.1016/j.ejogrb.2023.05.031. Epub 2023 May 27. Eur J Obstet Gynecol Reprod Biol. 2023. PMID: 37276726 Free article. Review.
OBJECTIVE: Current opinion on the superiority of fondaparinux versus low molecular-weight heparin (LMWH) in treating recurrent miscarriage is controversial. This meta-analysis aimed to comprehensively compare the pregnancy outcomes and adverse events in patients with recur …
OBJECTIVE: Current opinion on the superiority of fondaparinux versus low molecular-weight heparin (LMWH) in treating recurrent miscar …
2,275 results